TP53 and B-cell chronic lymphocytic leukemia: Additionally, AZD6738 sensitized primary CLL cells with such defects to chemotherapy and ibrutinib, suggesting ATR as a promising therapeutic target for TP53- or ATM-defective CLL [221].